Ftse Mib
33.821,94
0,22%
DAX
17.948,34
0,15%
S&P 500
5.018,39
-0,34%
NASDAQ Composite
15.605,48
-0,33%
Bitcoin
58.269,80
0,05%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Theravance Biopharma Inc (TBPH) Theravance Biopharma Inc (TBPH) Notizie

Theravance Biopharma Inc

TBPH
8,84
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 10:37:32
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
29/4/202412:00PRNUSTheravance Biopharma to Report First Quarter 2024 Financial..
10/4/202412:00PRNUSTheravance Biopharma, Inc. to Host Virtual Key Opinion..
26/2/202422:16EDGAR2Form 8-K - Current report
26/2/202422:05PRNUSTheravance Biopharma, Inc. Reports Fourth Quarter and Full..
23/2/202402:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202402:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202402:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202402:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202402:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202412:00PRNUSTheravance Biopharma to Participate in an Upcoming Investor..
17/2/202402:12EDGAR2Form 3 - Initial statement of beneficial ownership of..
14/2/202422:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202412:00PRNUSTheravance Biopharma to Report Fourth Quarter and Full Year..
16/1/202412:16EDGAR2Form 8-K - Current report
05/1/202412:07EDGAR2Form 8-K - Current report
05/1/202412:00PRNUSTheravance Biopharma Announces Results from the Phase 4..
28/12/202312:01EDGAR2Form 8-K - Current report
27/12/202300:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202300:06EDGAR2Form 3 - Initial statement of beneficial ownership of..
21/12/202323:10EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
21/12/202323:06EDGAR2Form 8-K - Current report
21/12/202323:00PRNUSTheravance Biopharma, Inc. Announces Appointment of Jeremy..
18/12/202312:00PRNUSTheravance Biopharma to Conduct Investor Meetings During the..
23/11/202300:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/11/202300:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/11/202300:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/11/202300:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202300:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/11/202312:00PRNUSTheravance Biopharma to Present New Ampreloxetine Data at..
15/11/202312:00PRNUSTheravance Biopharma to Participate in the 6th Annual..
13/11/202314:00PRNUSViatris and Theravance Biopharma Announce Positive Top-Line..
09/11/202322:46EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202322:53EDGAR2Form 8-K - Current report
07/11/202322:28PRNUSTheravance Biopharma, Inc. Reports Third Quarter 2023..
01/11/202323:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/10/202322:15EDGAR2Form 8-K - Current report
19/10/202312:00PRNUSTheravance Biopharma to Report Third Quarter 2023 Financial..
19/10/202300:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/10/202322:13EDGAR2Form 144 - Report of proposed sale of securities
19/9/202300:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/9/202322:24EDGAR2Form 144 - Report of proposed sale of securities
12/9/202312:05EDGAR2Form 8-K - Current report
29/8/202312:00PRNUSTheravance Biopharma to Participate in an Upcoming Investor..
28/8/202312:05PRNUSTheravance Biopharma to Present New Ampreloxetine Data at..
25/8/202300:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202300:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202300:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202300:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202300:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/8/202300:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: Min: Max:
Chiusura: 8,84

La tua Cronologia

NASDAQ
TBPH
Theravance Biopharma
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network